<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37108090</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Increased Immunoglobulin Gamma-3 Chain C in the Serum, Saliva, and Urine of Patients with Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6927</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24086927</ELocationID><Abstract><AbstractText>Immunoglobulin gamma-3 chain C (IGHG3) levels have been detected in the blood and tissue of patients with systemic lupus erythematosus (SLE). This study aims to assess its clinical value by measuring and comparing levels of IGHG3 in different body fluids in patients with SLE. The levels of IGHG3 in saliva, serum, and urine from 181 patients with SLE and 99 healthy controls were measured and analyzed. In patients with SLE and healthy controls, salivary IGHG3 levels were 3078.9 &#xb1; 2473.8 and 1413.6 &#xb1; 1075.3 ng/mL, serum IGHG3 levels were 478.1 &#xb1; 160.9 and 364.4 &#xb1; 97.9 &#x3bc;g/mL, and urine IGHG3 levels were 64.0 &#xb1; 74.5 and 27.1 &#xb1; 16.2 ng/mL, respectively (all <i>p</i> &lt; 0.001). Salivary IGHG3 was correlated with ESR (correlation coefficient [r], 0.173; <i>p</i> = 0.024). Serum IGHG3 was correlated with leukocyte count (r, -0.219; <i>p</i> = 0.003), lymphocyte count (r, 0.22; <i>p</i> = 0.03), anti-dsDNA antibody positivity (r, 0.22; <i>p</i> = 0.003), and C3 levels (r, -0.23; <i>p</i> = 0.002). Urinary IGHG3 was correlated with hemoglobin level (r, -0.183; <i>p</i> = 0.021), ESR (r, 0.204; <i>p</i> = 0.01), anti-dsDNA antibody positivity (r, 0.262; <i>p</i> = 0.001), C3 levels (r, -0.202; <i>p</i> = 0.011), and SLE disease activity index (r, 0.332; <i>p</i> = 0.01). Urinary IGHG3 was higher in patients with nephritis than in those without (119.5 &#xb1; 110.0 vs. 49.8 &#xb1; 54.4 ng/mL; <i>p</i> &lt; 0.01). IGHG3 was increased in the saliva, serum, and urine of patients with SLE. While salivary IGHG3 was not identified to be specific to SLE disease activity, serum IGHG3 showed correlations with clinical characteristics. Urinary IGHG3 levels were associated with disease activity and renal involvement in SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Ju-Yang</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Won</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-2827-0884</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-5706-9629</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Wook-Young</ForeName><Initials>WY</Initials><Identifier Source="ORCID">0000-0002-2501-4439</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyoun-Ah</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0003-2609-3367</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Chang-Hee</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0001-6156-393X</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HR16C0001</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country>Republic of Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009393" MajorTopicYN="Y">Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001826" MajorTopicYN="Y">Body Fluids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">immunoglobulin G</Keyword><Keyword MajorTopicYN="N">saliva</Keyword><Keyword MajorTopicYN="N">serum</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">urine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37108090</ArticleId><ArticleId IdType="pmc">PMC10138548</ArticleId><ArticleId IdType="doi">10.3390/ijms24086927</ArticleId><ArticleId IdType="pii">ijms24086927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Long H., Yin H., Wang L., Gershwin M.E., Lu Q. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J. Autoimmun. 2016;74:118&#x2013;138. doi: 10.1016/j.jaut.2016.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.06.020</ArticleId><ArticleId IdType="pubmed">27396525</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Nagafuchi Y., Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11:928. doi: 10.3390/biom11070928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070928</ArticleId><ArticleId IdType="pmc">PMC8301935</ArticleId><ArticleId IdType="pubmed">34206696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J.Y., Nam J.Y., Ryu K.S., Son I.O., Shin J.H., Baek W.Y., Kim H.A., Suh C.H. Salivary immunoglobulin Gamma-3 chain C is a promising noninvasive biomarker for systemic lupus erythematosus. Int. J. Mol. Sci. 2021;22:1374. doi: 10.3390/ijms22031374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031374</ArticleId><ArticleId IdType="pmc">PMC7866502</ArticleId><ArticleId IdType="pubmed">33573068</ArticleId></ArticleIdList></Reference><Reference><Citation>Damelang T., Rogerson S.J., Kent S.J., Chung A.W. Role of IgG3 in infectious diseases. Trends Immunol. 2019;40:197&#x2013;211. doi: 10.1016/j.it.2019.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.01.005</ArticleId><ArticleId IdType="pubmed">30745265</ArticleId></ArticleIdList></Reference><Reference><Citation>den Dunnen J., Vogelpoel L.T., Wypych T., Muller F.J., de Boer L., Kuijpers T.W., Zaat S.A., Kapsenberg M.L., de Jong E.C. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and Fc&#x3b3;RIIa in human dendritic cells. Blood. 2012;120:112&#x2013;121. doi: 10.1182/blood-2011-12-399931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-12-399931</ArticleId><ArticleId IdType="pubmed">22649103</ArticleId></ArticleIdList></Reference><Reference><Citation>de Taeye S.W., Bentlage A.E.H., Mebius M.M., Meesters J.I., Lissenberg-Thunnissen S., Falck D., S&#xe9;nard T., Salehi N., Wuhrer M., Schuurman J., et al. Fc&#x3b3;R binding and ADCC activity of human IgG allotypes. Front. Immunol. 2020;11:740. doi: 10.3389/fimmu.2020.00740.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00740</ArticleId><ArticleId IdType="pmc">PMC7218058</ArticleId><ArticleId IdType="pubmed">32435243</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard D., Eloranta M.L., Hagberg N., Berggren O., Tandre K., Alm G., R&#xf6;nnblom L. Activated T cells enhance interferon-&#x3b1; production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann. Rheum. Dis. 2016;75:1728&#x2013;1734. doi: 10.1136/annrheumdis-2015-208055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208055</ArticleId><ArticleId IdType="pubmed">26493814</ArticleId></ArticleIdList></Reference><Reference><Citation>Newling M., Fiechter R.H., Sritharan L., Hoepel W., van Burgsteden J.A., Hak A.E., van Vollenhoven R.F., van de Sande M.G.H., Baeten D.L.P., den Dunnen J. Dysregulated Fc&#x3b3; receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients. Clin. Exp. Immunol. 2020;199:39&#x2013;49. doi: 10.1111/cei.13371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13371</ArticleId><ArticleId IdType="pmc">PMC6904640</ArticleId><ArticleId IdType="pubmed">31509231</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 2014;5:520. doi: 10.3389/fimmu.2014.00520.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00520</ArticleId><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiteri V.A., Goodall M., Doutch J., Rambo R.P., Gor J., Perkins S.J. Solution structures of human myeloma IgG3 antibody reveal extended Fab and Fc regions relative to the other IgG subclasses. J. Biol. Chem. 2021;297:100995. doi: 10.1016/j.jbc.2021.100995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100995</ArticleId><ArticleId IdType="pmc">PMC8371214</ArticleId><ArticleId IdType="pubmed">34302810</ArticleId></ArticleIdList></Reference><Reference><Citation>McLay J., Leonard E., Petersen S., Shapiro D., Greenspan N.S., Schreiber J.R. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J. Immunol. 2002;168:3437&#x2013;3443. doi: 10.4049/jimmunol.168.7.3437.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.7.3437</ArticleId><ArticleId IdType="pubmed">11907102</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenspan N.S., Monafo W.J., Davie J.M. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: Enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies. J. Immunol. 1987;138:285&#x2013;292. doi: 10.4049/jimmunol.138.1.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.138.1.285</ArticleId><ArticleId IdType="pubmed">2431057</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss S., Jonsson A., Bottermann M., Watkinson R., Lode H.E., McAdam M.B., Michaelsen T.E., Sandlie I., James L.C., Andersen J.T. Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge. Sci. Immunol. 2022;7:eabj1640. doi: 10.1126/sciimmunol.abj1640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj1640</ArticleId><ArticleId IdType="pmc">PMC7614286</ArticleId><ArticleId IdType="pubmed">35486676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoepel W., Allahverdiyeva S., Harbiye H., de Taeye S.W., van der Ham A.J., de Boer L., Zaat S.A.J., van Weeghel M., Baeten D.L.P., Houtkooper R.H., et al. IgG subclasses shape cytokine responses by human myeloid immune cells through differential metabolic reprogramming. J. Immunol. 2020;205:3400&#x2013;3407. doi: 10.4049/jimmunol.2000263.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000263</ArticleId><ArticleId IdType="pubmed">33188071</ArticleId></ArticleIdList></Reference><Reference><Citation>Snapper C.M., McIntyre T.M., Mandler R., Pecanha L.M., Finkelman F.D., Lees A., Mond J.J. Induction of IgG3 secretion by interferon gamma: A model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 1992;175:1367&#x2013;1371. doi: 10.1084/jem.175.5.1367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.175.5.1367</ArticleId><ArticleId IdType="pmc">PMC2119217</ArticleId><ArticleId IdType="pubmed">1373759</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlev A.N., Malkiel S., Kurata-Sato I., Dorj&#xe9;e A.L., Suurmond J., Diamond B. Fc&#x3b3;RIIB regulates autoantibody responses by limiting marginal zone B cell activation. J. Clin. Investig. 2022;132:e157250. doi: 10.1172/JCI157250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI157250</ArticleId><ArticleId IdType="pmc">PMC9435648</ArticleId><ArticleId IdType="pubmed">35819855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G.G., Li J.M. IgG subclass serum levels in systemic lupus erythematosus patients. Clin. Rheumatol. 2009;28:1315&#x2013;1318. doi: 10.1007/s10067-009-1224-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-009-1224-x</ArticleId><ArticleId IdType="pubmed">19597698</ArticleId></ArticleIdList></Reference><Reference><Citation>Alahlafi A.M., Wordsworth P., Wojnarowska F. The distribution of IgG subclasses in the lupus band suggests disease-specific alteration in subclass switching rather than polyclonal B-cell activation. Clin. Exp. Dermatol. 2004;29:288&#x2013;292. doi: 10.1111/j.1365-2230.2004.01520.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2230.2004.01520.x</ArticleId><ArticleId IdType="pubmed">15115513</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoura Z., Koutouzov S., Chabre H., Cacoub P., Amoura I., Musset L., Bach J.F., Piette J.C. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43:76&#x2013;84. doi: 10.1002/1529-0131(200001)43:1&lt;76::AID-ANR10&gt;3.0.CO;2-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200001)43:1&lt;76::AID-ANR10&gt;3.0.CO;2-I</ArticleId><ArticleId IdType="pubmed">10643702</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Li P., Wu D., Xu D., Hou Y., Wang Q., Li M., Li Y., Zeng X., Zhang F., et al. Serum IgG subclasses in autoimmune diseases. Medicine. 2015;94:e387. doi: 10.1097/MD.0000000000000387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000000387</ArticleId><ArticleId IdType="pmc">PMC4602543</ArticleId><ArticleId IdType="pubmed">25590841</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening J.J., D&#x2019;Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., et al. Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;530. doi: 10.1111/j.1523-1755.2004.00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Erausquin C., Merino R., Izui S., Fernandez-Sueiro L., Saez F., Fernandez F., Rodriguez-Valverde V., Merino J. Therapeutic effect of early thymic irradiation in (NZB x NZW)F1 mice, associated with a selective decrease in the levels of IgG3 and gp70-anti-gp70 immune complexes. Cell Immunol. 1995;161:207&#x2013;212. doi: 10.1006/cimm.1995.1028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cimm.1995.1028</ArticleId><ArticleId IdType="pubmed">7697731</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S., Nose M., Sasaki J., Yamamoto T., Kyogoku M. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J. Immunol. 1991;147:515&#x2013;519. doi: 10.4049/jimmunol.147.2.515.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.147.2.515</ArticleId><ArticleId IdType="pubmed">2071894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijl M., Dijstelbloem H.M., Oost W.W., Bootsma H., Derksen R.H., Aten J., Limburg P.C., Kallenberg C.G. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology. 2002;41:62&#x2013;67. doi: 10.1093/rheumatology/41.1.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/41.1.62</ArticleId><ArticleId IdType="pubmed">11792881</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabuuchi J., Hoshino J., Mizuno H., Ozawa Y., Sekine A., Kawada M., Sumida K., Hiramatsu R., Hayami N., Yamanouchi M., et al. Immunoglobulin G subclass 3 in ISN/RPL lupus nephritis classification. Clin. Nephrol. 2019;91:32&#x2013;39. doi: 10.5414/CN109459.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CN109459</ArticleId><ArticleId IdType="pubmed">30431429</ArticleId></ArticleIdList></Reference><Reference><Citation>Junker F., Gordon J., Qureshi O. Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation. Front. Immunol. 2020;11:1393. doi: 10.3389/fimmu.2020.01393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01393</ArticleId><ArticleId IdType="pmc">PMC7350606</ArticleId><ArticleId IdType="pubmed">32719679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuniga R., Markowitz G.S., Arkachaisri T., Imperatore E.A., D&#x2019;Agati V.D., Salmon J.E. Identification of IgG subclasses and C-reactive protein in lupus nephritis: The relationship between the composition of immune deposits and FCgamma receptor type IIA alleles. Arthritis Rheum. 2003;48:460&#x2013;470. doi: 10.1002/art.10930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10930</ArticleId><ArticleId IdType="pubmed">12571856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A.M., Alarc&#xf3;n G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>